淋巴瘤资料9.pdf

Leukemia Lymphoma, June 2007; 48(6): 1092 – 1101 ORIGINAL ARTICLE: CLINICAL Cladribine combined with cyclophosphamide and mitoxantrone is an active salvage therapy in advanced non-Hodgkin’s lymphoma TADEUSZ ROBAK, EWA LECH-MARANDA, AGNIESZKA JANUS, JERZY BLONSKI, AGNIESZKA WIERZBOWSKA, JOANNA GORA-TYBOR 4 1 / 2 Department of Hematology, Medical University of Lodz, Poland 1 / 8 0 n o (Received 22 January 2007; revised 20 March 2007; accepted 21 March 2007) y t i s r e v i n U n Abstract a w The aim of this study was to determine the feasibility, efficacy and toxicity of the combined therapy consisting of cladribine o R (2-CdA), mitoxantrone and cyclophosphamide (CMC regimen) in patients with refractory or relapsed non-Hodgkin’s y b lymphoma (NHL). Thirty six patients, 14 with mantle cell lymphoma (MCL), 10 with diffuse large B-cell lymphoma m . o y (DLBCL), 5 with follicular lymphoma (FL), 3 with small lymphocytic lymphoma (SLL), and 4 with T-cell lymphoma were c l . n e o enrolled to the study. The CMC protocol consisted of 2-CdA at a dose of 0.12 mg/kg in a 2-hour infusion on days 1 through r a e 2 2 c s 3, mitoxantrone 10 mg/m i.v. on day 1 and cyclophosphamide 650 mg/m i.v. on day 1. The CMC courses were repeated at h u t l l intervals of 4 weeks. Thirty three patients were available for evaluation of response. Overall response rate (OR) was 58% a a e n h o (95% CI, 41 – 75%). Seven patients (21%; 95% CI, 7 – 35%) achieved a complete response (CR) and 12 patient